SEER News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SE

Mkt Cap

$112.7M

Volume

142.43K

Next Earnings

November 5th

Loading chart

SE

SEERSeer, Inc. Class A Common Stock

SEER

Pay with—

Available Balance0.00

SE

Mkt Cap

$113.0M

Volume

142.43K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual MeetingSeer, Inc. announced the re-election of all seven director nominees to its Board of Directors based on preliminary voting results from its 2026 Annual Meeting of Stockholders held on July 28, 2026. The company expressed confidence in its board's qualifications and commitment to advancing shareholder interests, while outlining its strategic focus on expanding platform utilization, securing biobank studies, advancing innovation, and scaling commercialization with cost discipline.GlobeNewswire Inc. · Jul 28, 2026

Seer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation PotentialSeer, Inc. filed an investor presentation ahead of its July 28, 2026 Annual Meeting, highlighting progress against strategic goals including 62% CAGR in installed base growth, 36% decrease in annual cash burn since 2022, and a robust innovation pipeline. The company's Board unanimously recommends voting for its seven director nominees and opposes activist investors Bradley Radoff and Michael Torok's campaign to force an early sale, arguing their proposals lack actionable value creation ideas and their nominees lack relevant proteomics expertise.GlobeNewswire Inc. · Jul 6, 2026

Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC GroupSeer, Inc. announced it has received an unsolicited acquisition proposal from Bradley L. Radoff and Michael Torok (Radoff-JEC Group) to acquire all outstanding Class A common stock for $2.25 per share in cash plus a contingent value right. The Radoff-JEC Group has also nominated three director candidates for the 2026 Annual Meeting. Seer's Board will carefully review the proposal and present its formal recommendation in the definitive proxy statement.GlobeNewswire Inc. · Apr 13, 2026

Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026Seer, Inc. announced its participation in the 2026 U.S. Human Proteome Organization (US HUPO) Annual Conference with over a dozen scientific presentations showcasing how its Proteograph Product Suite enables deep, scalable proteomics research across cardiovascular disease, neurodegeneration, aging biology, and oncology. The company will feature a breakfast symposium on nanoparticle-enabled plasma proteomics and multiple plenary and poster presentations demonstrating the technology's ability to detect thousands of proteins from small-volume samples.GlobeNewswire Inc. · Feb 19, 2026

Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025Seer presented multiple scientific studies at HUPO 2025, demonstrating how their Proteograph platform enables deep proteomics research across cardiovascular, aging, and cancer biology, showcasing the technology's potential for population-scale discovery and clinical translation.GlobeNewswire Inc. · Nov 7, 2025

Next-Gen Proteomics Market Size, Trends, Competitive Analysis – Towards HealthcareThe next-generation proteomics market is projected to expand rapidly between 2025-2034, driven by technological advancements, rising chronic disease prevalence, and increasing demand for personalized medicine across pharmaceutical, biotechnology, and diagnostic sectors.GlobeNewswire Inc. · Oct 24, 2025

Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025Seer showcased how proteomics complements genomics in precision medicine research at the American Society of Human Genetics 2025 conference, presenting multiple scientific studies demonstrating the potential of their Proteograph Product Suite to uncover novel biomarkers and enhance disease understanding.GlobeNewswire Inc. · Oct 10, 2025

Seer (SEER) Q2 Revenue Jumps 32%Seer, a life sciences technology firm, reported Q2 2025 revenue of $4.1 million, exceeding analyst expectations by 9.3% and representing a 32% year-over-year increase. Despite revenue growth, the company remains unprofitable with continued operating losses.The Motley Fool · Aug 7, 2025

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young AdultsSeer, Inc. and Korea University are launching a large-scale proteomics study to identify biomarkers for early cancer detection in young adults, leveraging Seer's Proteograph platform and Thermo Scientific's Orbitrap Astral mass spectrometer.GlobeNewswire Inc. · Jun 1, 2025

Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025Seer, Inc. will showcase new findings at the 21st Annual US Human Proteome Organization (HUPO) Conference, including a case study on a novel co-delivery therapeutic platform for targeting cancer vulnerabilities with siRNA and mRNA therapeutics.GlobeNewswire Inc. · Feb 20, 2025

to start trading

SE

SEERSeer, Inc. Class A Common Stock

SEER

Pay with—

Available Balance0.00

Your PositionYou don't own any SEER yet.

Related Tickers

Earnings